Synthesis of Aromatase Inhibitors and Dual Aromatase Steroid Sulfatase Inhibitors by Linking an Arylsulfamate Motif to 4-(4H-1,2,4-triazol-4-ylamino)benzonitrile: SAR, Crystal Structures, in vitro and in vivo Activities

被引:24
作者
Bubert, Christian [1 ,2 ]
Woo, L. W. Lawrence [1 ,2 ]
Sutcliffe, Oliver B. [1 ,2 ]
Mahon, Mary F. [3 ]
Chander, Surinder K. [4 ]
Purohit, Atul [4 ]
Reed, Michael J. [4 ]
Potter, Barry V. L. [1 ,2 ]
机构
[1] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
[2] Univ Bath, Sterix Ltd, Bath BA2 7AY, Avon, England
[3] Univ Bath, Dept Chem, Bath BA2 7AY, Avon, England
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, St Marys Hosp, Sterix Ltd, London W2 1NY, England
关键词
aromatase inhibitors; breast cancer; dual aromatase-sulfatase inhibitors; endocrine therapy; sulfatase inhibitors;
D O I
10.1002/cmdc.200800164
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
4-(((4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino)methyl)phenyl sulfamate (6a) was the first dual aromatase-sulfatase inhibitor (DASI) reported. Several series of its derivatives with various linker systems between the steroid sulfatase (STS) and the aromatase inhibitory pharmacophores were synthesised and evaluated in JEG-3 cells. The X-ray crystal structures of the aromatase inhibitors, DASI precursors 42d and 60, and DASI 43h were determined. Nearly all derivatives show improved in vitro aromatase inhibition over 6a but decreased STS inhibition. The best aromatase inhibitor is 42e (IC(50)=0.26 nm) and the best DASI is 43e (IC(50 aromatase) = 0.45 nm, IC(50STS) = 1200 nm). SAR for aromatase inhibition shows that compounds containing an olkylene- and thioether-based linker system are more potent than those that are ether-, sulfone-, or sulfonamide-based, and that the length of the linker has a limited effect on aromatase inhibition beyond two methylene units. Compounds 43d-f were studied in vivo (10 mg kg(-1), single, p.o.). The most potent DASI is 43e, which inhibited PMSG-induced plasma estradiol levels by 92% and liver STS activity by 98% 3 h after dosing. These results further strengthen the concept of designing and developing DASIs for potential treatment of hormone-related cancers.
引用
收藏
页码:1708 / 1730
页数:23
相关论文
共 49 条
[1]  
ADAMS J, 1981, CANCER RES, V41, P4720
[2]   HYDRAZINSULFONSAURE-AMIDE .1. UBER DAS HYDRAZODISULFAMID [J].
APPEL, R ;
BERGER, G .
CHEMISCHE BERICHTE-RECUEIL, 1958, 91 (06) :1339-1341
[3]   SOME CARDIOVASCULAR EFFECTS OF A SERIES OF ARYLOXYALKYLAMINES .1. [J].
AUGSTEIN, J ;
AUSTIN, WC ;
BOSCOTT, RJ ;
GREEN, SM ;
WORTHING, CR .
JOURNAL OF MEDICINAL CHEMISTRY, 1965, 8 (03) :356-&
[4]  
Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO
[5]  
2-Y
[6]   Synthesis and digestibility inhibition of diarylheptanoids: Structure-activity relationship [J].
Bratt, K ;
Sunnerheim, K .
JOURNAL OF CHEMICAL ECOLOGY, 1999, 25 (12) :2703-2713
[7]   Aromatase inhibitors in the treatment of breast cancer [J].
Brueggemeier, RW ;
Hackett, JC ;
Diaz-Cruz, ES .
ENDOCRINE REVIEWS, 2005, 26 (03) :331-345
[8]   Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues [J].
Chetrite, GS ;
Cortes-Prieto, J ;
Philippe, JC ;
Wright, F ;
Pasqualini, JR .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2000, 72 (1-2) :23-27
[9]   ANDROSTENEDIONE AND ANDROST-5-ENE-3-BETA, 17-BETA-DIOL STIMULATE DMBA-INDUCED RAT MAMMARY-TUMORS - ROLE OF AROMATASE [J].
DAUVOIS, S ;
LABRIE, F .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 13 (01) :61-69
[10]   Steroid sulfatase inhibitors [J].
Horvath, A ;
Billich, A .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (11) :1541-1553